hepatitis B virus–related hepatocellular carcinoma
Conditions
Interventions
1:Orally entecavir
2:Oral tenofovir
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 69 Years
Inclusion criteria
Inclusion criteria: 1. older than 18 years and less than 69 years old; 2. HBsAg positiveHCV antibody negative and HIV antibody negative; 3. HBV-DNA>200 IU/mL; 4. BCLC stagingO ? A stage; 5. Platelet100×10^9/L; 6. Liver function Child-Pugh A,with no invasion in portal vein, hepatic vein and two large branches, no extrahepatic metastasis; 7. CCR= 70 mL/min; 8. Antiviral treatment was not performed before surgery or antiviral treatment was accepted in a short term (<3 months); 9. No treatment was performed before the operation. The results of postoperatively histopathological biopsy were HCC; 10. The patients agree to participate in the clinical trial.
Exclusion criteria
Exclusion criteria: 1. The image found extrahepatic lymph nodes or visceral metastasis, the existence of large vascular invasion, the existence of bile duct embolus in the first operation; 2. The patient combined with a malignant tumor of other organs or had a history of other malignant tumors in other organs; 3. Liver function decompensation, such as: upper gastrointestinal bleeding, refractory ascites, coagulation dysfunction and so on; 4. contraindications to surgery; 5. Patients with poor compliance and not adhered to the follow-ups; 6. Patients refused to participate in the clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg;HBsAb;HBeAg;HBeAb;HBcAb;interferona;interferon ß;interferon ?; | — |
Secondary
| Measure | Time frame |
|---|---|
| AFP;PIVKA-II;Abdominal ultrasound; | — |
Countries
China
Contacts
Public ContactLi Chuan
West China Hospital, Sichuan University
Outcome results
None listed